ACCELERATOR

We provide a complete toolkit that includes business, scientific, and financial resources. Our network includes seasoned executives, world-class research institutions, and top-tier investors with extensive experience in transforming science into commercial products... Accelerator established Proniras in 2017 to develop tezampanel, a small molecule compound in-licensed from Eli Lilly and Company. Proniras secured grant funding to evaluate tezampanel as a countermeasure for nerve agent-induced seizures. Recognizing that there were opportunities to develop tezampanel for patients suffering from opiate withdrawal, Proniras refocused its strategy and secured additional grant funding from the National Institute on Drug Abuse (NIDA) to support this effort... Biotech value creation requires teamwork. We work as a team to help scientific visionaries build breakthrough biotech companies.

Primary location: New York United States